Literature DB >> 15679764

Rebound acid hypersecretion after long-term inhibition of gastric acid secretion.

R Fossmark1, G Johnsen, E Johanessen, H L Waldum.   

Abstract

BACKGROUND: Rebound acid hypersecretion develops after the use of acid inhibitors. AIM: To estimate the duration of hypersecretion and to elucidate the role of the enterochromaffin-like (ECL) cell in rebound acid hypersecretion.
METHODS: Patients waiting for anti-reflux surgery who had used a proton pump inhibitor daily > 1 year were included. All patients discontinued taking acid inhibiting drugs after the operation. Basal and pentagastrin stimulated acid output was measured at 4, 8, 16 and 26 weeks postoperatively. Oxyntic mucosal biopsies were collected before and 26 weeks after the operation for counting of histidine decarboxylase (HDC) immunoreactive cells. Serum chromogranin A (CgA) and gastrin were measured before and at 4, 8, 16 and 26 weeks after the operation.
RESULTS: Pentagastrin stimulated acid secretion was higher at 4 and 8 weeks than at 26 weeks after the operation. Gastrin and CgA were significantly reduced at 4 and 8 weeks, respectively. The number of HDC immunoreactive cells was reduced by 60% at 26 weeks postoperative. DISCUSSION: Rebound acid hypersecretion lasts more than 8 weeks, but less than 26 weeks after long-term proton pump inhibition.
CONCLUSION: The findings indicate that not only the parietal cell mass, but also ECL cell mass and activity are involved in the mechanism of acid hypersecretion.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15679764     DOI: 10.1111/j.1365-2036.2004.02271.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  16 in total

1.  Oral proton-pump inhibitors and step-down therapy for nonulcer dyspepsia: is this the right approach?

Authors:  Helge L Waldum; Tom C Martinsen; Oyvind Hauso; Gunnar Qvigstad
Journal:  Therap Adv Gastroenterol       Date:  2010-03       Impact factor: 4.409

2.  Mechanism of acid hypersecretion post curative gastrinoma resection.

Authors:  Jeremiah V Ojeaburu; Tetsuhide Ito; Pellegrino Crafa; Cesare Bordi; Robert T Jensen
Journal:  Dig Dis Sci       Date:  2010-08-20       Impact factor: 3.199

Review 3.  Physiological and clinical significance of enterochromaffin-like cell activation in the regulation of gastric acid secretion.

Authors:  Guanglin Cui; Helge L Waldum
Journal:  World J Gastroenterol       Date:  2007-01-28       Impact factor: 5.742

Review 4.  To be or not to be: The host genetic factor and beyond in Helicobacter pylori mediated gastro-duodenal diseases.

Authors:  Dipanjana Datta De; Susanta Roychoudhury
Journal:  World J Gastroenterol       Date:  2015-03-14       Impact factor: 5.742

Review 5.  Discontinuing Long-Term PPI Therapy: Why, With Whom, and How?

Authors:  Laura Targownik
Journal:  Am J Gastroenterol       Date:  2018-03-20       Impact factor: 10.864

Review 6.  Gastroesophageal reflux disease in children and adolescents: when and how to treat.

Authors:  Matthew W Carroll; Kevan Jacobson
Journal:  Paediatr Drugs       Date:  2012-04-01       Impact factor: 3.022

Review 7.  [Newly recognized side-effects of proton pump inhibitors. Arguments in favour of fundoplication for GERD?].

Authors:  B H A von Rahden; M Scheurlen; J Filser; H J Stein; C-T Germer
Journal:  Chirurg       Date:  2012-01       Impact factor: 0.955

8.  Treatment options in pediatric GERD.

Authors:  Neelesh A Tipnis; Colin D Rudolph
Journal:  Curr Treat Options Gastroenterol       Date:  2007-10

Review 9.  Step-up and step-down approaches to treatment of gastroesophageal reflux disease in children.

Authors:  Eric Hassall
Journal:  Curr Gastroenterol Rep       Date:  2008-06

Review 10.  Comparative safety and efficacy of proton pump inhibitors in paediatric gastroesophageal reflux disease.

Authors:  Jaroslaw Kierkus; Grzegorz Oracz; Bartosz Korczowski; Edyta Szymanska; Anna Wiernicka; Marek Woynarowski
Journal:  Drug Saf       Date:  2014-05       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.